What type of targeted therapy does dacomitinib/dacomitinib belong to?

Dacomitinib/Dacomitinib (Dacomitinib) is an oral targeted non-small cell lung cancer treatment drug targeting epidermal growth factor receptor (EGFR) mutations. It is a second-generation EGFR tyrosine kinase inhibitor (TKI). This type of drug inhibits cancer cells by interfering with the EGFR signaling pathway in tumor cells and blocking cell growth and division.

Different from the first generationEGFR-TKI such as gefitinib and erlotinib, dacomitinib uses an irreversible binding mechanism and has a wider range of targets. In addition to EGFR, it can also inhibit related proteins such as HER2 and HER4, thus providing a more comprehensive blocking effect on tumor growth. This pan-HER inhibitory feature makes it theoretically more effective in certain clinical scenarios, especially in patients who require broader-spectrum EGFR pathway control.

Despite this, the use of dacomitinib is still mainly concentrated in patients with non-small cell lung cancer who are confirmed to have EGFR sensitive mutations (such as exon 19 deletion or L858R mutation). The drug is indicated as a first-line option for the treatment of locally advanced or metastatic disease. Although it has a strong targeting effect, due to its irreversible and multi-target mechanism, it is easy to cause a series of side effects related to the EGFR pathway, including rash, diarrhea, oral ulcers and onychomycosis. These adverse reactions affect the patient's tolerance and quality of life to a certain extent. Therefore, in clinical use, close monitoring is required and the dose needs to be adjusted according to individual conditions.

In general, dacomitinib represents an important node in the evolution of targeted therapy from the first generation to higher generations. The upgrade of its mechanism provides a new treatment strategy for EGFR mutant lung cancer patients, and also promotes a more precise personalized medical process.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro